Data Visualizations

Five different PD-1 inhibitors generate at least $1 billion in annual revenue as of 2024, including Keytruda, the bestselling drug of all time. The entire drug class generated over $45 billion in global revenue in 2023, the most of all-time. But advances in precisely targeting the tumor microenvironment could make them even more valuable.

Crops engineered with genetic traits dominate major American crop acreage because they provide farmers value, convenience, and greatly improved yields.

Blockbuster drugs generated 62% of total global revenue from the United States in 2023. The top 20 bestsellers often had even higher dependencies on American patients.

Verve Therapeutics pivoted from VERVE-101 to VERVE-102. Preliminary results from a phase 1 study in hypercholesterolemia are expected in the first half of 2025.

The precommercial drug developer decided to pause development of two preclinical programs in the second half of 2023 to navigate difficult capital markets. The moves helped to slow growth in R&D expenses for the next 12 months (and counting).

Relay Therapeutics intends to find a global development partner to commercialize lirafugratinib. Although the asset will earn regulatory approval in a rare bile duct cancer called cholangiocarcinoma (CCA), regulators requested a larger study in the larger tumor-agnostic opportunity.

Biopharma, agriculture, and government customers accounted for 70% of Cell Engineering segment revenue in mid-2024, up from 33% in early 2021.

Amgen is evaluating olpasiran in a 6,000-patient study that's expected to be completed in late 2026. A successful outcome would mark a significant win for creator Arrowhead Pharmaceuticals.

The DNA synthesis pioneer is increasingly driven by next-generation sequencing (NGS) applications and synthetic genes, which comprised 84% of total revenue in the fiscal third quarter of 2024.

In the three years ended June 30, 2024, the number of accounts placing orders at Twist Bioscience grew 25%, but revenue more than doubled. How did that happen?

As of July 18, 2024, only 14 companies in history have achieved a market valuation of at least $1 trillion when measured in June 2024 U.S. dollars. None have been biotech companies.

The largest drug developers aren't even close to having the scale of Big Tech. Obesity drugs could more than double the performance of the bestselling drugs in history -- and it still wouldn't enable the scale or profitability of information tech leaders.

The iPhone has cumulative sales of $1.84 trillion through 17 years on the market. That's more than humanity spends on all drug products each year.

The iPhone generates more revenue every 46 days than the world's all-time bestselling drug generated during its record-setting year.

The DNA sequencing leader raised only $36 million in venture capital and just $96 million at its IPO. Illumina achieved its first operating profit eight years after being founded and has been cash flow positive since 2006.

Exact Sciences reports that compliance rates increase with rescreen eligibility. Individuals see a 20% higher compliance rate for their first rescreen and a 30% higher compliance rate for their second rescreen.

Biologic therapeutic modalities, primarily antibodies, were significantly more likely to be a top 20 bestselling drug product than small molecule therapeutic modalities. That will change as GLP-1 agonists rise up the leaderboard. Despite being peptides, they're short enough for the FDA to classify them as small molecules.

Roche owned the most blockbuster drug products with 15 in 2023, but seven companies wielded at least 10 blockbusters. A bestselling drug is a golden ticket to stardom, however, as the smallest company to market a blockbuster has a valuation of over $12 billion.

Oncology, cardiometabolic, and autoimmune treatments were responsible for over half of all 152 blockbuster drug products in 2023. But hidden in the long tail of data was a blockbuster medicine for dogs.

The Cologuard owner and precision oncology company delivered positive operating cash flow in 2023, although operating profits were still a year or two away based on the year-end trajectory.

Although the liquid-biopsy pioneer has grown revenue at a healthy clip, it hasn't generated operating leverage from scaling. An unfavorable level of Medicare coverage for the Shield colon cancer screening product might jeopordize the survival of the business.

If a lab hardware company doesn't have a path to generate at least 67% of total revenue from consumables, then it will fail to become a sustainable business.

The RNAi specialist has offset $948.7 million in R&D expenses from 2018 through June 2024 by monetizing pipeline assets. While the milestone payouts are getting larger, they're also becoming less frequent. That's led to lumpier cash flow.

Big pipelines require big budgets. At least in the case of Arrowhead Pharmaceuticals, a focus on RNA interference (RNAi) suggests the ambitious plans will be a good long-term investment. It's the "long-term" part that will test the resolve of investors.

If Americans paid the same prices for Humira as international patients, then the United States would have saved over $100 billion from 2014 to 2023.

PI3K-alpha mutations are the most common undrugged target in cancer, present in an estimated 14% of all solid tumor cancers. They're difficult to safely inhibit due to their role in glucose metabolism.

Solt DB combed over dozens of financial filings from multiple countries to build the most comprehensive dataset of global blockbuster drugs.

A blockbuster drug product has at least $1 billion in annual revenue. However, American patients accounted for nearly 60% of total blockbuster sales in 2023.

From Lipitor (launched 1996) to Humira (launched 2002), no drug product has notched more revenue in its sixth year on the market than Ozempic (launched 2017). It was primarily used off label to treat obesity.

The outster of longtime CEO John Melo and bankruptcy of the company followed critical reporting by Solt DB detailing nearly a decade of abuses by management.